Thirty-nine adult patients with human immunodeficiency virus infection and oral candidiasis were randomly assigned to receive either one fluconazole capsule (100 mg) or five clotrimazole troches (10 mg each) daily for 14 days. Among 36 evaluable patients, clinical resolution rates were 100 and 65%, respectively (P = 0.018). Mycological eradication rates were 75 and 20%, respectively (P = 0.004). Fluconazole-treated patients were more likely to remain disease free during follow-up than those treated with clotrimazole (P = 0.014 at 2 weeks). Prolonged clinical responses correlated with mycological eradication at the end of therapy (P = 0.043).
Fluconazole is a new bis-triazole antifungal agent with good bioavailability, low protein binding, a volume of distribution which approximates total body water, and a long serum half-life (5) . Favorable results have been obtained by using fluconazole as a treatment for oropharyngeal candidiasis both in noncomparative studies (1, 3; P. R. Farrow, K. W. Brammer, and J. M. Feczko, Program Abstr. 27th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 949, 1987 ) and in comparison with ketoconazole (2) . In this paper, we report the results of a prospective, randomized trial comparing the efficacy (both clinical and mycological) of and the tolerance to fluconazole with the efficacy of and tolerance to clotrimazole troches in the management of oropharyngeal candidiasis in patients infected with human immunodeficiency virus (HIV).
After disease free during follow-up than those treated with clotrimazole (P = 0.014 at day 28). Eight of twelve patients (four in each treatment group) who had positive cultures at the end of therapy had relapsed by day 42. In contrast, negative cultures were obtained from 8 of the 10 patients (8 of 9 taking fluconazole and 0 of 1 taking clotrimazole) who remained disease free 4 weeks posttherapy (P = 0.043). There were no serious side effects in either group. Nausea was the major subjective complaint and occurred in three patients in each group. In two of the three clotrimazoletreated patients, this nausea, along with altered taste sensations, resulted in premature discontinuation of therapy.
Complete blood counts including leukocyte differential and platelets, prothrombin time, blood urea nitrogen, creatinine, total bilirubin, and liver enzymes (aspartate transaminase, alanine transaminase, gamma-glutamyl-transpeptidase, and alkaline phosphatase) were drawn at baseline. Follow-up laboratory tests were performed on days 7 and 14 of therapy to detect any potential toxicities. One patient in each treatment group had moderate elevations of liver enzymes, a condition which may have been drug-related.
Compliance with treatment regimens was assessed by counting the number of pills returned at each evaluation point during the treatment period. Patients taking fluconazole (one capsule daily) were uniformly compliant. Only two patients in the clotrimazole group, however, completely followed the treatment regimen (one troche five times daily) for the full 14 days as prescribed. The average number of troches missed by these patients throughout the study period was 6 (range, 3 to 12) of 70 prescribed. The patient who was deemed an early failure because of worsening disease actually took more than the prescribed five troches per day prior to discontinuation. Reasons for noncompliance included forgetfulness, the inconvenience of taking multiple doses, and altered taste sensations. This study showed that fluconazole was more effective than clotrimazole troches in the treatment of HIV-infected patients with oral candidiasis. Prolonged clinical responses following 14 days of therapy were related, at least in part, to better mycological eradication, although previous studies have not shown such a relationship (1, 2) . Better compliance and tolerance of fluconazole also might have accounted for some of its superior efficacy. The documented efficacy of fluconazole, its ease of administration, and the overall high tolerance of patients to it make this drug an attractive alternative for the treatment of oropharyngeal candidiasis in the HIV-infected population. The exact dosage, the duration of therapy, and the need for maintenance therapy still need to be defined. In individual patients, tolerance of topical agents, severity of disease, and cost should be important considerations in drug choice.
